Delgocitinib Synthesis: Key Patents and Production Insights
The industrial-scale synthesis of delgocitinib involves specific patented processes [1]. These patents are crucial for understanding the manufacturing and commercialization of the drug.
What patents cover delgocitinib manufacturing?
Patents related to delgocitinib's synthesis detail the chemical pathways and methodologies employed for its production. These intellectual property protections are vital for the drug's developer, enabling exclusive manufacturing and sales rights for a defined period. Information on specific synthesis patents can be found through patent databases and specialized resources like DrugPatentWatch.com [1].
How is delgocitinib manufactured industrially?
Industrial synthesis of pharmaceuticals like delgocitinib typically involves multi-step chemical reactions, purification, and formulation processes. The patented methods outline the specific reagents, conditions, and sequences designed for efficiency, yield, and purity on a large scale [1]. These processes are developed to be robust and reproducible to meet regulatory standards for drug manufacturing.
When do delgocitinib's synthesis patents expire?
The expiration dates of delgocitinib's synthesis patents are critical for determining when generic versions of the drug may become available. Patent expiry dates vary depending on the specific patent and the jurisdictions in which they are filed. Detailed patent expiry information is available through resources such as DrugPatentWatch.com, which tracks patent landscapes for pharmaceutical products [1].
Who is developing delgocitinib?
Delgocitinib is developed by AnaptysBio, Inc. [2]. The drug is approved in Japan for the treatment of atopic dermatitis, palmoplantar pustulosis, and other inflammatory skin diseases [3].
What is the mechanism of action for delgocitinib?
Delgocitinib is an orally available janus kinase (JAK) inhibitor. It selectively inhibits JAK1, JAK2, JAK3, and TYK2, which play roles in the signaling pathways of various cytokines that contribute to inflammation and immune responses [2][3].
How does delgocitinib compare to other atopic dermatitis treatments?
Delgocitinib offers a targeted approach by inhibiting multiple JAKs involved in inflammatory pathways. Other treatments for atopic dermatitis include topical corticosteroids, calcineurin inhibitors, and other systemic immunomodulators. The specific efficacy and safety profiles, along with the route of administration and mechanism of action, differentiate delgocitinib from these alternatives.
Sources:
1. DrugPatentWatch.com
2. AnaptysBio, Inc. Press Release. (n.d.). Retrieved from https://www.anaptysbio.com/
3. AnaptysBio, Inc. SEC Filings. (n.d.). Retrieved from https://www.anaptysbio.com/